, Tracking Stock Market Picks
Enter Symbol:
Teva Pharmaceutical Industries Limited (TEVA) [hlAlert]

up 14.48 %

Teva Pharmaceutical Industries Limited (TEVA) rated Buy with price target $64 by Argus

Posted on: Tuesday,  Nov 25, 2014  9:25 AM ET by Argus

Argus rated Buy Teva Pharmaceutical Industries Limited (NYSE: TEVA) on 11/25/2014, when the stock price was $56.95. Since
then, Teva Pharmaceutical Industries Limited has gained 14.49% as of 09/01/2015's recent price of $65.20.
If you would have followed this Argus's recommendation on TEVA, you would have gained 14.48% of your investment in 280 days.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson?s disease and respiratory products. Teva?s active pharmaceutical ingredient business provides vertical integration to Teva?s own pharmaceutical production and sells to third party manufacturers. The Company?s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/25/2014 9:25 AM Buy
56.95 64.00
as of 10/17/2014
1 Week down  -1.29 %
1 Month down  -2.34 %
3 Months down  -4.67 %
1 YTD up  0.11 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/6/2014 12:00 AM Buy
51.08 58.00
2/25/2013 8:25 AM Hold
7/13/2011 8:25 AM Buy
49.29 58.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy